Newly diagnosed myeloma study using blood-marker risk groups
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed, untreated, symptomatic multiple myeloma (not smoldering), with documented organ or bone involvement
- You have measurable myeloma markers in blood and/or urine (such as M-protein or abnormal free light chains)
- Your myeloma test results fit the study’s required risk category and gene-expression pattern (from the study’s specific testing)
- You are between 18 and 70 years old and can attend study visits and follow the plan
- You are healthy enough for stem-cell collection and high-dose melphalan (your doctor must think this is safe)
- You can follow strict pregnancy prevention rules (especially important if you can become pregnant) and agree to regular pregnancy testing if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests the best combination of medicines for newly diagnosed multiple myeloma patients who are headed to an autologous stem cell transplant (ASCT). It compares extended VRD plus versus Isa-VRD versus Isa-V-Iberdomide to see which approach works best and is tolerable.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for newly diagnosed multiple myeloma in patients who cannot or choose not to have a stem cell transplant. The goal is to see if this combination helps control myeloma and improve survival.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This trial tests a combination of four drugs (elranatamab, isatuximab, bortezomib, and lenalidomide) for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this combination is safe and effective.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.